Clinical trial of carrelizumab injection approved
April 29, 2025
Source: drugdu
90
Hengrui Medicine(600276) announced on the evening of April 27 that its subsidiary Suzhou Shengdia Biopharmaceutical Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" for injection of carrelizumab approved by the National Medical Products Administration, and will conduct clinical trials in the near future. Carrelizumab injection is a humanized anti-PD-1 monoclonal antibody that can bind to the human PD-1 receptor and block the PD-1/PD-L1 pathway, restoring the body's anti-tumor immunity, thereby forming a cancer immunotherapy base.
https://finance.eastmoney.com/a/202504273390129236.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Humanwell Pharmaceuticals’ RFUS-949 tablet clinical trial approved May 31, 2025
- The clinical trial of STC007 injection of Sunshine Novo’s subsidiary has achieved the expected goal May 31, 2025
- The National Medical Products Administration conditionally approved the marketing of Trastuzumab for injection May 31, 2025
- Moderna withdraws its application for the launch of the new crown/influenza combined vaccine, and its share price fell more than 6% during the session May 31, 2025
- Jimin Health’s hospitals and Dabo Biotech signed a strategic cooperation agreement to expand the layout of cell and gene therapy pipeline May 31, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
